Resonandina

Company profile

Resonandina: A pioneer in sustainable medical leasing

Resonandina is a profitable, sustainable medical lease scale-up founded in the Netherlands, dedicated to making diagnostics accessible to everyone. By offering pay-per-use leasing of high-quality, capital-intensive diagnostic and treatment equipment (MRI, PET/CT, Linac and more), Resonandina bridges the gap for hospitals that lack the resources or expertise to acquire such solutions. This model not only provides access to advanced equipment but also ensures economic and social returns in all activities.

Problem: Hospitals often lack resources or knowledge for capital-intensive medical equipment.

Solution: Resonandina developed an innovative all-inclusive pay-per-use medical lease model that makes diagnostics and treatment accessible for everyone.

Capital-intensive equipment becomes affordable for hospitals because a small amount has to be paid each month instead of a large lump sum. The key differentiator of Resonandina is the focus on a ‘simple’ and client-oriented “B2B” business model based on “Pay-per-Use” lease with an “all-inclusive” package. The service includes project design, investment, installation, training, full maintenance, and extended life cycle (with upgrades, reuse, and recycling). The hospital has all medical-related responsibilities such as patient logistics, quality management, liability and (insurance) invoicing.

Resonandina ensures that these hospitals can deploy advanced equipment so that diagnostics become affordable and available to all. This results in healthier people and fewer travel movements.

Resonandina started its services in 2015 in Bolivia with a step-by-step expansion across Latin America and the Caribbean. Submarkets are: “doctor owned” medium-size hospitals, larger professionally managed hospitals, and Public Healthcare Services.

Having a unique concept of “use it, don’t own it”, Resonandina has established a solid presence in the niche of high-end diagnostic and treatment equipment, supported by strong partnerships with GE Healthcare and Varian/Siemens Healthineers. Fundamental is the recurring revenue model with long-term (8+ years) contracts. With 16 units currently producing and 5 additional projects in installation and near-term pipeline, the company continues to expand its operational base.

Resonandina's 'Steady Growth' scenario targets 40+ projects and €27.5+ million ARR by 2030. Nevertheless the ambition goal is 75+ projects with €55 million ARR by 2030. Resonandina has successfully created a recognized market position, defined the service and operational execution, managed to create rising ARR and profitability, proven the concept, prepared footprints in the addressable markets and is ready for the next phase of growth. The current strategic focus remains primarily on the “home market” in the Americas, including expansion the USA. At a later stage expansion to other continents is optional.

Use of funds

While previous rounds mainly financed MRI installations in Latin America and the Caribbean, the 7th round was the first in cancer treatment (Linac) and diagnostics (PET/CT). This 8th campaign follows this line and will finance a Linear Accelerator (Linac) in a hospital in Peru, used in radiotherapy to treat cancer.

A Linac (Linear Accelerator) accelerates electrons in a straight line to generate high-energy X-rays, which are directed precisely at tumors during the therapy session. This destroys cancer cells while minimizing damage to healthy tissue. Because the radiation can be shaped to the exact contours of the tumor, treatment is both effective and highly targeted.

Developments since the last funding round with Invesdor

Find out more about what has happened since the last crowdfunding.

Back to top ▲

Company info 

Products and services

Resonandina developed an innovative sustainable medical lease model that makes diagnostics and radiotherapy accessible for everyone, while creating predictable, asset-backed recurring revenue streams.

High-quality equipment

Aligning with ongoing technological medical developments, hospitals need equipment that meets the highest standards - certified and guaranteed by leading manufacturers. Main areas of equipment include:

• General Medicine, Traumatology, Orthopedics, Neurosurgery, Oncology, Cardiology (MRI, CT, Cath-Lab).
• Radiotherapy (Linear Accelerator – Linac, Brachytherapy).
• Nuclear Medicine (Cyclotron, PET/CT).

Resonandina focuses exclusively on high-end, capital-intensive medical equipment with strong secondary market value and long economic lifecycles. This ensures durable assets that serve both clinical impact and investor security.

Full-service maintenance

Resonandina provides comprehensive, long-term maintenance without hidden fees. This includes:

• Project design and site planning.
• Delivery and installation.
• Training, monitoring, and maintenance.
• Upgrades and parts replacement to extend the equipment’s lifespan.

All services are executed by the OEM (e.g. GE Healthcare, Varian) or certified third parties, ensuring reliability, operational continuity, and preservation of asset value throughout the contract period.

By outsourcing technical responsibility to first-class manufacturers and certified service providers, operational risk is reduced and uptime is maximized - supporting stable cash flows.

Long-term commitment

Through long-term partnerships (typically 8-10 years), hospitals can focus on patient diagnostics and treatment, while Resonandina manages the equipment’s technical functionality and output optimization.

Minimum volume agreements and pay-per-use structures provide visibility on revenues while aligning incentives between Resonandina and the hospital. This results in reliable, efficient operations and recurring income backed by essential medical infrastructure.

Upgrade and reuse

At the end of a contract, equipment is upgraded to meet evolving technological and clinical expectations. Parts are reused or recycled where possible, enhancing sustainability and extending the equipment’s life cycle.

For example, Resonandina’s MRI program extends the life span of an MRI from approximately 90,000 scans to up to 135,000 scans. This approach not only reduces waste but also improves capital efficiency and long-term asset utilization.

Back to top ▲

How does it work?

The pay-per-use system, combined with volume discounts, incentivizes hospitals to maximize equipment usage, improving both efficiency and profitability. Resonandina offers a practical, transparent, and affordable financial solution for hospitals, while creating predictable recurring revenues.

By integrating flexible leasing solutions with comprehensive services, Resonandina ensures that hospitals can focus on patient care while improving operational efficiency, balance sheet flexibility, and long-term financial sustainability.

Back to top ▲

Business model

Resonandina employs a unique business model that revolutionizes access to capital-intensive medical equipment by shifting the financial burden from upfront investment (CAPEX) to operational expenses (OPEX). This approach ensures that hospitals can acquire and operate state-of-the-art diagnostic and radiotherapy equipment without compromising their financial stability.

Financial model

Resonandina’s financial model is built on a pay-per-use system, where hospitals pay a fee for each diagnostic scan or treatment performed. This structure aligns costs directly with usage, making the service scalable and economically viable for healthcare providers.

Volume discounts incentivize hospitals to increase equipment utilization by lowering the cost per procedure as usage grows. Additionally, hospitals commit to a minimum volume after a grace period, guaranteeing a stable recurring revenue stream for Resonandina while promoting optimal equipment use.

Hospitals generate income from each scan or treatment by billing patients or insurers based on local tariffs. All countries have a private and public healthcare insurance system. This tiered pricing model supports hospital profitability while maintaining predictable recurring revenues for Resonandina.

On average, Resonandina generates approximately €250,000 to €350,000 in annual recurring revenue for every €1 million invested in medical equipment, depending on modality and utilization levels.

The typical payback period of a device is approximately four years, while the economic lifetime of the equipment ranges between 10 and 15 years with proper maintenance.

Contractual and client details

Resonandina enters into long-term lease agreements that typically last between 8 and 15 years, aligning with the economic life cycle of the equipment.

There are three primary market segments:

• Medium-sized, doctor-owned clinics
• Larger professionally managed hospital groups
• Public Healthcare Services

The main focus is on the ‘doctor-owned’ clinics. All institutions face capital constraints or strategic capital allocation decisions. Resonandina’s leasing solution allows them to preserve liquidity while expanding diagnostic and treatment capacity.

Comprehensive service offering

Resonandina’s service package provides end-to-end support for hospitals, ensuring smooth and reliable operation:

• Equipment acquisition and project structuring
• Delivery, installation, and site planning
• Full-service maintenance and technical monitoring
• Technological upgrades and parts replacement
• Staff training and operational support

This integrated model reduces operational risk, protects asset value, and maximizes equipment uptime - directly supporting recurring revenue stability.

Partnerships and operational support

Resonandina collaborates with leading original equipment manufacturers (OEMs) such as GE Healthcare and Varian/Siemens Healthineers, alongside certified local service providers.

These partnerships ensure:

• High-quality installations
• Reliable maintenance
• Access to certified spare parts
• Compliance with international medical standards

Outsourcing technical responsibility to first-class partners enhances operational reliability and preserves collateral value.

Sustainability focus

At the core of Resonandina’s model is a commitment to sustainability. Equipment is upgraded, refurbished, or reused at the end of each contract, minimizing waste and reducing environmental impact.

For example, Resonandina’s MRI lifecycle program extends the usable scan capacity of an MRI from approximately 90,000 to up to 135,000 scans, optimizing capital efficiency and resource use.

This approach aligns with SDG 12 (Responsible Consumption and Production) and strengthens long-term asset utilization.

Vision and mission

• Vision: Support healthier populations through equitable access to diagnostic care and cancer treatment.
• Mission: Make high-quality diagnostics and radiotherapy accessible through innovative, sustainable pay-per-use leasing models.

Back to top ▲

Market

Market opportunity

The radiotherapy and diagnostic imaging market in the Americas continues to offer significant structural growth potential.

In the United States, approximately 4,000 Linear Accelerators are installed, which in theory meets the international benchmark of around four devices per one million inhabitants. However, more than half of these systems are older than ten years, and distribution remains uneven across regions and patient groups. This creates an ongoing replacement need even in mature markets.

In Latin America and the Caribbean, approximately 800 Linear Accelerators are currently installed. To reach international benchmark levels, an estimated additional 1,600+ devices would be required. A substantial portion of the installed base is also more than ten years old, indicating both expansion and replacement demand.

Beyond radiotherapy, demand for MRI, PET/CT and CT systems continues to increase, driven by population growth, urbanization, expanding healthcare coverage, and a growing middle class in emerging markets.

Within this environment, the main challenge is often not medical demand, but access to capital and financing structures that enable hospitals to deploy advanced equipment.

Back to top ▲

Competition and USP

Competitive landscape

The market for high-end diagnostic and radiotherapy equipment is traditionally dominated by global OEMs such as GE Healthcare, Varian/Siemens Healthineers, Philips and others. These companies primarily operate through direct equipment sales, typically supported by conventional bank financing.

Such models require hospitals to commit substantial upfront capital, maintain sufficient balance sheet strength, and secure local financing capacity. In many emerging markets, these requirements create structural barriers, limiting access to advanced medical infrastructure despite clear clinical demand.

Resonandina operates in this financing and implementation gap. Rather than focusing on equipment sales, the company structures long-term pay-per-use lease agreements, combining financing, installation, and lifecycle management into one integrated solution.

Differentiation and positioning

Resonandina’s differentiation lies in its integrated medical lease model. The company retains ownership of the equipment and enters into long-term contractual relationships with hospitals, typically ten years for radiation therapy machines (Linac). Revenues are generated through usage-based payments supported by minimum volume agreements, creating recurring income streams linked to essential healthcare infrastructure.

Because the model combines cross-border financing, technical partnerships with OEMs, and long-term hospital contracts, entry barriers are relatively high. Significant capital requirements, operational complexity, regulatory considerations, and the need for established local relationships limit the number of comparable providers.

Over time, Resonandina has built a growing installed base across the Americas, fuelled by recurring revenues and increasing operational scale. This positions the company as a specialized provider within the niche of sustainable medical leasing.

Back to top ▲

Management

Back to top ▲

Company structure

Ownership and governance

Resonandina Holanda B.V. is fully owned by QMED B.V., a private holding company controlled by founder and CEO Floriaan van Bemmelen and his family.

This ownership structure ensures clear governance and long-term strategic continuity. Strategic decisions, capital allocation, and expansion plans are determined at holding level. Since its founding in 2015, the company has grown under founder-led management while progressively professionalizing its organization.

Back to top ▲

Developments at company name since the last crowdfunding

The company’s development over the past year reflects continued growth and further professionalization. Key developments include:

• Financial performance: EBITDA increased from approximately €1.8 million in 2024 to around €2.5 million in 2026. For 2026, EBITDA is expected to be approximately €3.5 million.
• Project delivery: In 2025, five projects were successfully installed. Three additional installations were postponed and are expected to be completed in 2026. These timing shifts affect short-term results but do not change the overall project pipeline.
• Strengthened capital base: 2025 solvency increased to approximately 22%, supported by retained earnings and the formalization of a €2 million subordinated loan.
• Market expansion: In cooperation with Varian, steps have been taken to explore opportunities in underserved regions in Mexico and the United States, complementing the established presence in the Americas.
• Organizational development: The team has expanded and internal processes have been further professionalized, reducing operational dependency on individual management members and strengthening scalability.

Together, these developments indicate steady operational growth and increasing maturity of the organization compared to earlier funding rounds..

Back to top ▲

Use of funds

The funds raised in this round will be used to finance the installation of a Linear Accelerator (Linac) in a hospital in Cusco, Peru, or alternatively in a similar underserved region in Peru.

Cancer remains one of the leading causes of death globally, and access to radiotherapy infrastructure remains uneven in many regions of Latin America. The installation of this Linac in Cusco strengthens local cancer treatment capacity and reduces the need for patients to travel long distances for care.

A Linac is advanced radiotherapy equipment used in cancer treatment. It generates high-energy X-rays that are precisely directed at tumors, enabling targeted destruction of cancer cells while minimizing damage to surrounding healthy tissue. The installation of this equipment expands local radiotherapy capacity and improves access to modern cancer treatment.

The financing amount for this round is up to €2,500,000. Depending on the total amount raised, the following funding scenarios are possible:

Back to top ▲

Actual and planned figures

Get an insight in to the company's financial figures, such as turnover and earnings development. Learn more about the growth forecast.

Security

Risks

Investing in growth companies always involves risks. Below you can find the detailed list of risks related to this investment, as described in the Key Investment Information Sheet (KIIS). Please review this information carefully before making your investment decision.

Back to top ▲

Investment related documents

Log in for more information.

There are currently no updates available.

This section will be regularly updated with new, project-relevant information as the financing progresses. To be informed about new updates in a timely manner, subscribe to our newsletter.